Metra signs agreement with Beckman Coulter:
This article was originally published in Clinica
Metra Biosystems has formed a cross-licensing agreement with Beckman Coulter for a US patent owned by the latter company. Metra can continue to develop and sell the Alkphase-B formation marker under Beckman's patents and in exchange, Beckman Coulter gains the rights to develop, commercialise and sell Metra's Pyrilinks-D test for use on its automated laboratory analyser, the Access immunoassay system. The Pyrilinks-D test is a method for assaying urine samples for levels of deoxypyrid inoline, a marker of bone resorption.
You may also be interested in...
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.
The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.